サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1678778

がんバイオマーカー検査の世界市場 (2025年～2033年)

Global Cancer Biomarker Testing Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
がんバイオマーカー検査の世界市場 (2025年～2033年)
出版日: 2025年03月11日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

がんバイオマーカー検査の世界市場は2024年に248億6,000万米ドルに達し、2033年には677億4,000万米ドルに達すると予測され、予測期間2025年のCAGRは11.5%で成長する見込みです。

がんバイオマーカー検査は、がんの存在や進行を示す生物学的マーカーを分析します。バイオマーカーには、がん細胞やがんに反応して体内で産生されるタンパク質、遺伝子、その他の物質が含まれます。がんバイオマーカー検査の主な用途は、早期発見、診断、予後予測、治療効果の評価です。

患者のがんに特異的なバイオマーカーを同定することで、より個別化された治療計画が可能になり、最も効果的な治療法が選択されるようになります。バイオマーカー検査は、診断精度の向上、治療選択の指針、がん再発の兆候のモニタリングに極めて重要です。

市場力学：

促進要因と抑制要因

がん罹患率の上昇

医療システムが早期発見、個別化治療、継続的モニタリングの改善に注力していることから、がん罹患率の上昇ががんバイオマーカー検査市場の成長を大きく牽引すると予想されます。世界のがん患者数の増加に伴い、より早期で治療可能な段階でがんを特定し、患者の転帰を改善できる精密な診断ツールに対する需要が非常に高まっています。例えば、国際がん研究機関によると、2022年に新たに診断される肺がん症例は146万件です。前立腺がんの新規症例数は、2025年には313万人に達すると予想されています。がん症例数の増加に伴い、さまざまなバイオマーカーの需要が高まることが予想されます。

バイオマーカー検査は、標的治療を可能にし、試行錯誤の治療法を減らし、副作用を最小限に抑えます。さらに、ゲノム研究の進歩とともに精密医療が重視されるようになり、バイオマーカー検査がより身近で効果的なものとなりつつあります。世界のがん罹患率の上昇に伴い、医療提供者や研究者は治療を調整し、患者のケアを改善するためにバイオマーカー検査を採用する傾向が強まっており、市場の拡大に拍車をかけています。

バイオマーカー検査の高額な費用

がんバイオマーカー検査には高いコストがかかるため、特に資源が限られている環境では、こうした技術の普及に大きな課題となっています。これらの検査はしばしば最先端技術や専門的な知識に依存しており、そのため価格が高騰しています。すでに予算の制約に苦しんでいる医療システムにとって、日常診療にバイオマーカー検査を組み込むことは、財政的に困難な決断となります。この経済的障壁は、早期発見と個別化治療の利用を制限するだけでなく、世界的にがん医療への公平なアクセスを確保するため、より手頃な価格のソリューションの必要性を強調しています。

目次

第1章 分析手法と分析範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がんの発症率の上昇
      • ゲノムと分子調査の進歩
    • 抑制要因
      • バイオマーカー検査の高コスト
      • 規制と承認の課題
    • 機会
      • モニタリングのための液体生検とがんバイオマーカー検査の統合
    • 影響分析

第5章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と主要企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析：ベストケース・ベースケース・ワーストケースの予測
  • 価格分析と価格市場力学
  • キーオピニオンリーダー (KOL)

第6章 検査の種類別

  • 遺伝子バイオマーカー検査
  • タンパク質バイオマーカー検査
  • 循環腫瘍DNA（ctDNA）検査
  • ポリメラーゼ連鎖反応（PCR）
  • 次世代シーケンシング（NGS）
  • その他

第7章 製品種類

  • 装置
    • PCR（ポリメラーゼ連鎖反応）装置
    • 次世代シーケンシング（NGS）プラットフォーム
    • 質量分析計
    • ctDNA（循環腫瘍DNA）検出装置
    • その他
  • キット・試薬

第8章 がんの種類別

  • 肺がん
  • 前立腺がん
  • 乳がん
  • 白血病
  • その他

第9章 用途別

  • 創薬・医薬品開発
  • 疾患スクリーニング
  • 治療計画
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • その他ラテンアメリカ地域
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
    • 企業概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 製品販売の実績・予測
      • 製品販売量
    • 財務概要
      • 企業の収益
      • 収益シェア：地域別
      • 収益予測
    • 主な発展
      • 企業合併・買収 (M&A)
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Guardant Health
  • Agilent Technologies, Inc.
  • Quanterix
  • Exact Sciences Corporation
  • QIAGEN
  • Takara Bio Inc.

第13章 付録

目次
Product Code: CD9270

The global cancer biomarker testing market reached US$24.86 billion in 2024 and is expected to reach US$67.74 billion by 2033, growing at a CAGR of 11.5% during the forecast period 2025-2033.

Cancer biomarker testing analyzes biological markers that indicate the presence or progression of cancer. These biomarkers can include proteins, genes, or other substances produced by cancer cells or by the body in response to cancer. The primary applications of cancer biomarker testing are early detection, diagnosis, prognosis prediction, and assessing how well treatments are working.

Identifying specific biomarkers in a patient's cancer enables more personalized treatment plans, ensuring that the most effective therapies are selected. Biomarker testing is crucial for enhancing diagnosis accuracy, guiding treatment choices, and monitoring for any signs of cancer recurrence.

Market Dynamics: Drivers & Restraints

Rising Incidence of Cancer

The rising incidence of cancer is expected to significantly drive the growth of the cancer biomarker testing market as healthcare systems focus on improving early detection, personalized treatment, and ongoing monitoring. With an increasing number of cancer cases worldwide, there is a huge demand for precise diagnostic tools that can identify cancer at earlier, more treatable stages, enabling better patient outcomes. For instance, according to the International Agency for Research on Cancer, in 2022 there were 1.46 million new lung cancer cases diagnosed. The number of new prostate cancer cases is expected to reach 3.13 million in 2025. With the growing number of cancer cases, the demand for different biomarkers is expected to grow.

Biomarker testing allows for targeted therapies, reducing trial-and-error treatment methods and minimizing side effects, which is particularly important as cancer treatments become more complex. Additionally, the growing emphasis on precision medicine, along with advancements in genomic research, is making biomarker testing more accessible and effective. As the global cancer burden rises, healthcare providers and researchers are increasingly adopting biomarker testing to tailor treatments and improve patient care, fueling market expansion.

High Costs of Biomarker Tests

The high costs of cancer biomarker tests present a significant challenge to the widespread adoption of these technologies, particularly in resource-limited settings. These tests often rely on cutting-edge technologies and specialized expertise, driving up their price. For healthcare systems already struggling with budget constraints, integrating biomarker testing into routine care becomes a difficult financial decision. This economic barrier not only limits the availability of early detection and personalized treatment but also underscores the need for more affordable solutions to ensure equitable access to cancer care globally.

Segment Analysis

The global cancer biomarker testing market is segmented based on the test type, product type, cancer type, application, and region.

Next-generation sequencing (NGS) platforms are expected to dominate the cancer biomarker testing market.

Next-generation sequencing (NGS) refers to advanced sequencing technologies that allow for high-throughput, rapid, and cost-effective analysis of entire genomes or targeted regions of interest. In cancer biomarker testing, NGS has become a critical tool due to its ability to provide deep insights into the genetic makeup of tumors, enabling more precise detection, diagnosis, and treatment strategies.

Next-generation sequencing (NGS) platforms are poised to dominate the cancer biomarker testing market due to their unparalleled ability to provide comprehensive and high-throughput genomic insights. Several advanced next-generation sequencing tests and platforms are being introduced and research is advancing in improving these solutions to detect the cancers. For instance, in October 2024, NeoGenomics, Inc. launched its AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).

This capability significantly enhances early cancer detection, prognosis prediction, and monitoring of treatment responses. As the demand for precision medicine grows, NGS platforms are increasingly favored for their accuracy, scalability, and versatility, positioning them in a significant position in the market share.

Geographical Analysis

North America is expected to dominate the cancer biomarker testing market

North America holds a dominant position in the cancer biomarker testing market, driven by its sophisticated healthcare infrastructure and substantial investments in research and development. The region's access to cutting-edge technologies, including Next-Generation Sequencing (NGS) and liquid biopsy, accelerates the integration of advanced cancer biomarker testing into clinical practice.

The region's growth in the market is further enhanced by the presence of leading biotechnology and pharmaceutical companies, which are at the forefront of innovating and commercializing new biomarker tests, propelling market growth.

Moreover, North America's strong emphasis on precision medicine and personalized treatment further boosts demand for cancer biomarker testing, as it plays a crucial role in tailoring therapies to individual patients. The rising cancer incidence, coupled with an increasing focus on early detection and public awareness, has created a significant need for reliable diagnostic tools.

Competitive Landscape

The global market players in the cancer biomarker testing market are F. Hoffmann-La Roche Ltd, Illumina, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Guardant Health, Agilent Technologies, Inc., Quanterix, Exact Sciences Corporation, QIAGEN and Takara Bio Inc., among others.

Key Developments

  • In August 2024, Illumina, Inc. received Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications.
  • In April 2024, Takara Bio USA, Inc. launched its Shasta Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cancer biomarker testing market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Test Type
  • 3.2. Snippet by Product Type
  • 3.3. Snippet by Cancer Type
  • 3.4. Snippet by Application
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Incidence of Cancer
      • 4.1.1.2. Advances in Genomic and Molecular Research
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Biomarker Tests
      • 4.1.2.2. Regulatory and Approval Challenges
    • 4.1.3. Opportunities
      • 4.1.3.1. Integration of Cancer Biomarker Testing with Liquid Biopsy for Monitoring
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with the largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Test Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 6.1.2. Market Attractiveness Index, By Test Type
  • 6.2. Genetic Biomarker Testing*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Protein Biomarker Testing
  • 6.4. Circulating Tumor DNA (ctDNA) Testing
  • 6.5. Polymerase Chain Reaction (PCR)
  • 6.6. Next-Generation Sequencing (NGS)
  • 6.7. Others

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. PCR (Polymerase Chain Reaction) Machines
    • 7.2.4. Next-Generation Sequencing (NGS) Platforms
    • 7.2.5. Mass Spectrometers
    • 7.2.6. ctDNA (Circulating Tumor DNA) Detection Devices
    • 7.2.7. Others
  • 7.3. Kits & Reagents

8. By Cancer Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.1.2. Market Attractiveness Index, By Cancer Type
  • 8.2. Lung Cancer*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Prostate Cancer
  • 8.4. Breast Cancer
  • 8.5. Leukemia
  • 8.6. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Drug Discovery and Development*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Disease Screening
  • 9.4. Treatment Planning
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. Latin America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Mexico
      • 10.4.7.3. Argentina
      • 10.4.7.4. Rest of Latin America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Illumina, Inc.
  • 12.3. Thermo Fisher Scientific Inc.
  • 12.4. Bio-Rad Laboratories, Inc.
  • 12.5. Guardant Health
  • 12.6. Agilent Technologies, Inc.
  • 12.7. Quanterix
  • 12.8. Exact Sciences Corporation
  • 12.9. QIAGEN
  • 12.10. Takara Bio Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us